content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001674324</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001689375</issuerCik>
        <issuerName>Entrada Therapeutics, Inc.</issuerName>
        <secFileNumber>001-40969</secFileNumber>
        <issuerAddress>
          <com:street1>ONE DESIGN CENTER PLACE</com:street1>
          <com:street2>SUITE 17-500</com:street2>
          <com:city>BOSTON</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02210</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>857-305-1825</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>5AM Ventures V, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>TD Securities (USA) LLC</name>
          <address>
            <com:street1>1 Vanderbilt Ave</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>55735</noOfUnitsSold>
        <aggregateMarketValue>385128.85</aggregateMarketValue>
        <noOfUnitsOutstanding>37953417</noOfUnitsOutstanding>
        <approxSaleDate>06/27/2025</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>09/28/2017</acquiredDate>
        <natureOfAcquisitionTransaction>Venture Investment</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Entrada Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>55735</amountOfSecuritiesAcquired>
        <paymentDate>09/28/2017</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>06/27/2025</noticeDate>
        <signature>Andrew J. Schwab</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2780}]
text: 144
  0001674324
  XXXXXXXX
  LIVE
  0001689375
  Entrada Therapeutics, Inc.
  001-40969
  ONE DESIGN CENTER PLACE
  SUITE 17-500
  BOSTON
  MA
  02210
  857-305-1825
  5AM Ventures V, L.P.
  Director
  Common
  TD Securities (USA) LLC
  1 Vanderbilt Ave
  New York
  NY
  10017
  55735
  385128.85
  37953417
  06/27/2025
  NASDAQ
  Common
  09/28/2017
  Venture Investment
  Entrada Therapeutics, Inc.
  N
  55735
  09/28/2017
  Cash
  Y
  06/27/2025
  Andrew J. Schwab